vs

Side-by-side financial comparison of Penumbra Inc (PEN) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.

SouthState Bank Corp is the larger business by last-quarter revenue ($661.7M vs $385.4M, roughly 1.7× Penumbra Inc). SouthState Bank Corp runs the higher net margin — 34.1% vs 12.3%, a 21.8% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs 17.6%).

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.

PEN vs SSB — Head-to-Head

Bigger by revenue
SSB
SSB
1.7× larger
SSB
$661.7M
$385.4M
PEN
Higher net margin
SSB
SSB
21.8% more per $
SSB
34.1%
12.3%
PEN
Faster 2-yr revenue CAGR
SSB
SSB
Annualised
SSB
37.4%
17.6%
PEN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PEN
PEN
SSB
SSB
Revenue
$385.4M
$661.7M
Net Profit
$47.3M
$225.8M
Gross Margin
68.0%
Operating Margin
15.4%
15.1%
Net Margin
12.3%
34.1%
Revenue YoY
22.1%
Net Profit YoY
40.6%
153.5%
EPS (diluted)
$1.20
$2.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PEN
PEN
SSB
SSB
Q1 26
$661.7M
Q4 25
$385.4M
$581.1M
Q3 25
$354.7M
$599.7M
Q2 25
$339.5M
$577.9M
Q1 25
$324.1M
$544.5M
Q4 24
$315.5M
$369.8M
Q3 24
$301.0M
$351.5M
Q2 24
$299.4M
$350.3M
Net Profit
PEN
PEN
SSB
SSB
Q1 26
$225.8M
Q4 25
$47.3M
$247.7M
Q3 25
$45.9M
$246.6M
Q2 25
$45.3M
$215.2M
Q1 25
$39.2M
$89.1M
Q4 24
$33.7M
$144.2M
Q3 24
$29.5M
$143.2M
Q2 24
$-60.2M
$132.4M
Gross Margin
PEN
PEN
SSB
SSB
Q1 26
Q4 25
68.0%
Q3 25
67.8%
Q2 25
66.0%
Q1 25
66.6%
Q4 24
66.8%
Q3 24
66.5%
Q2 24
54.4%
Operating Margin
PEN
PEN
SSB
SSB
Q1 26
15.1%
Q4 25
15.4%
54.3%
Q3 25
13.8%
53.6%
Q2 25
12.0%
48.8%
Q1 25
12.4%
22.3%
Q4 24
13.6%
50.7%
Q3 24
11.7%
53.1%
Q2 24
-27.0%
49.3%
Net Margin
PEN
PEN
SSB
SSB
Q1 26
34.1%
Q4 25
12.3%
42.6%
Q3 25
12.9%
41.1%
Q2 25
13.3%
37.2%
Q1 25
12.1%
16.4%
Q4 24
10.7%
39.0%
Q3 24
9.8%
40.7%
Q2 24
-20.1%
37.8%
EPS (diluted)
PEN
PEN
SSB
SSB
Q1 26
$2.28
Q4 25
$1.20
$2.47
Q3 25
$1.17
$2.42
Q2 25
$1.15
$2.11
Q1 25
$1.00
$0.87
Q4 24
$0.88
$1.88
Q3 24
$0.75
$1.86
Q2 24
$-1.55
$1.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PEN
PEN
SSB
SSB
Cash + ST InvestmentsLiquidity on hand
$186.9M
$2.9B
Total DebtLower is stronger
Stockholders' EquityBook value
$1.4B
$9.0B
Total Assets
$1.8B
$68.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PEN
PEN
SSB
SSB
Q1 26
$2.9B
Q4 25
$186.9M
Q3 25
$321.0M
Q2 25
$421.8M
Q1 25
$376.1M
Q4 24
$324.4M
Q3 24
$280.5M
Q2 24
$288.3M
Stockholders' Equity
PEN
PEN
SSB
SSB
Q1 26
$9.0B
Q4 25
$1.4B
$9.1B
Q3 25
$1.4B
$9.0B
Q2 25
$1.3B
$8.8B
Q1 25
$1.2B
$8.6B
Q4 24
$1.2B
$5.9B
Q3 24
$1.1B
$5.9B
Q2 24
$1.2B
$5.7B
Total Assets
PEN
PEN
SSB
SSB
Q1 26
$68.0B
Q4 25
$1.8B
$67.2B
Q3 25
$1.7B
$66.0B
Q2 25
$1.7B
$65.9B
Q1 25
$1.6B
$65.1B
Q4 24
$1.5B
$46.4B
Q3 24
$1.5B
$46.1B
Q2 24
$1.5B
$45.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PEN
PEN
SSB
SSB
Operating Cash FlowLast quarter
$86.5M
Free Cash FlowOCF − Capex
$68.0M
FCF MarginFCF / Revenue
17.7%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
1.83×
TTM Free Cash FlowTrailing 4 quarters
$174.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PEN
PEN
SSB
SSB
Q1 26
Q4 25
$86.5M
$232.1M
Q3 25
$58.3M
$122.4M
Q2 25
$44.9M
$72.6M
Q1 25
$49.0M
$-126.3M
Q4 24
$51.1M
$354.3M
Q3 24
$56.5M
$-246.8M
Q2 24
$22.6M
$126.8M
Free Cash Flow
PEN
PEN
SSB
SSB
Q1 26
Q4 25
$68.0M
$215.5M
Q3 25
$42.0M
$101.7M
Q2 25
$29.4M
$52.5M
Q1 25
$35.5M
$-139.1M
Q4 24
$45.7M
$340.9M
Q3 24
$51.0M
$-254.2M
Q2 24
$18.1M
$117.3M
FCF Margin
PEN
PEN
SSB
SSB
Q1 26
Q4 25
17.7%
37.1%
Q3 25
11.8%
17.0%
Q2 25
8.7%
9.1%
Q1 25
11.0%
-25.5%
Q4 24
14.5%
92.2%
Q3 24
16.9%
-72.3%
Q2 24
6.0%
33.5%
Capex Intensity
PEN
PEN
SSB
SSB
Q1 26
Q4 25
4.8%
2.9%
Q3 25
4.6%
3.5%
Q2 25
4.6%
3.5%
Q1 25
4.2%
2.4%
Q4 24
1.7%
3.6%
Q3 24
1.8%
2.1%
Q2 24
1.5%
2.7%
Cash Conversion
PEN
PEN
SSB
SSB
Q1 26
Q4 25
1.83×
0.94×
Q3 25
1.27×
0.50×
Q2 25
0.99×
0.34×
Q1 25
1.25×
-1.42×
Q4 24
1.52×
2.46×
Q3 24
1.91×
-1.72×
Q2 24
0.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PEN
PEN

Thrombectomy$254.7M66%
Other$130.7M34%

SSB
SSB

Net Interest Income$561.6M85%
Noninterest Income$100.1M15%

Related Comparisons